Nanexa AB (FRA:40M) Short Interest


FRA:40M Nanexa AB FRA:40M
48 GF Score
Price €0.31
GF Value €0.17
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Nanexa AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:40M vs ZTS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nanexa AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanexa AB Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanexa AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Nanexa AB's Short Interest falls into.


FRA:40M
48GF Score
Nanexa AB FRA:40M
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nanexa AB (FRA:40M) Overvalued in 2026?

Based on GuruFocus' analysis, Nanexa AB stock appears to be overvalued. The current stock price of €0.31 is trading 83.2% above its estimated GF Value™ of €0.17. GuruFocus considers Nanexa AB to be Significantly Overvalued.

Key valuation signals for FRA:40M:

  • Short Interest:
  • GF Value™: €0.17 vs. price of €0.31 (83.2% above fair value)
  • GF Score™: 48/100 with 2 warning signs

No single metric tells the full story. See the FRA:40M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanexa AB Business Description

Other Exchanges NANEXA:Sweden
Address Virdings Alle 32B, Uppsala, SWE, 75450
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
48GF Score

Get the complete analysis for FRA:40M

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.31
Price
€0.17
GF Value